Clinical research
The hold follows a serious adverse event in which a study participant died after developing possible differentiation syndrome.
A study conducted by Athersys’ partner Healios on a potential treatment for ischemic stroke failed to meet the primary endpoint as its stock dropped 43%.
The 25th Annual Meeting of the American Society of Gene and Cell Therapy wrapped up on Thursday. BioSpace looks at some of the highlights.
Bayer has terminated a two year-old partnership with Atara to develop off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.
Anyone who has dealt with inflammatory skin conditions is familiar with what seems like a near-constant itch. That could become a thing of the past if ASLAN Pharma has something to say about it.
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
The FDA has a few target action dates for the end of the month, although PDUFA dates can sometimes seem like a moving target.
Zealand Pharma shared positive top-line results for its second Phase III clinical trial of its congenital hyperinsulinism (CHI) drug, dasiglucagon, in pediatric patients.
Janssen’s Tremfya, an IL-23 inhibitor, is showing an ability to separate itself from AbbVie’s Skyrizi in preventing the activation of cells that drive inflammation.
On Thursday, Mersana announced that the FDA granted an orphan drug designation to one of its lead assets, XMT-2056, which is intended to treat gastric cancer.
PRESS RELEASES